Skip to main content

Market Overview

Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm Cell Therapeutics And More


Conatus Pharmaceuticals Inc (NASDAQ: CNAT) +40% - The company announced plans to report top-line results of its clinical trials of Emricasan on January 8.

Cempra Inc (NASDAQ: CEMP) +15% - On Sunday, the company announced positive results from its pneumonia study; meeting primary and secondary objectives.

Immunomedics, Inc. (NASDAQ: IMMU) +8% - Shares are higher after the company won fast track designation for its IMMU-132 drug.

Cerus Corporation (NASDAQ: CERS) +6.7% - The company announced that its EU Phase 3 trial of INTERCEPT met primary endpoint.

ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) +3.7% - The company announced a deal with Johnson & Johnson’s Janssen Biotech Inc.

El Pollo LoCo Holdings Inc (NASDAQ: LOCO) +3.2% - Analysts at Baird upgraded shares to Outperform.

Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) -14% - Shares are lower following the company’s announcement of its final analysis of its phase 2a ALS study.

Starbucks Corporation (NASDAQ: SBUX) -1.4% - Analysts at Janney Capital downgraded Starbucks to Neutral and lowered the price target to $85.

Amgen, Inc. (NASDAQ: AMGN) -1.1% - Shares were downgraded to Equal-weight at Morgan Stanley.


Related Articles (AMGN)

View Comments and Join the Discussion!

Posted-In: Pre-Market Outlook Movers